Which drugs are most likely to be approved in Mixed Pain (Nociceptive Pain/Neuropathic Pain)?

Mixed Pain (Nociceptive Pain/Neuropathic Pain) disease is an indication for drug development with over 270 pipeline drugs currently active according to GlobalData.

Clinical Trial Payments: Optimizing the Path Forward for Site Payments

Jim DiCesare, Sr. Director, Study Operations, IQVIA Clinical Trial Payments Escalating competition for clinical trial sites, in tandem with other industry-wide challenges such as changing

January 10, 2024

CSL Vifor cutting 85 jobs in California

CSL Vifor will lay off 85 employees in the Bay Area following a strategic review conducted by CSL Behring, the parent company. The cuts are

September 7, 2023

Sotorasib Promising for KRAS–Related Vascular Malformations

Treating severe KRAS G12C-related arteriovenous malformations with sotorasib (Lumakras) appeared to be effective in a small French study. Two adult patients with the life-threatening condition

July 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.